glusod 10 mg film-coated tablets
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - empagliflozin 10 mg - drugs used in diabetes
glusod 25 mg film-coated tablets
medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - empagliflozin 25 mg - drugs used in diabetes
empala 10mg tablet 10 mg/1 tab
الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - empagliflozin 10 mg/1 tab - 10 mg/1 tab
empala 25mg tablet 25 mg/1 tab
الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - empagliflozin 25 mg/1 tab - 25 mg/1 tab
flozara 25 mg
الشركة الدولية للدواء - pharma international company - empagliflozin 25 mg - 25 mg
flozara 10 mg
الشركة الدولية للدواء - pharma international company - empagliflozin 10 mg - 10 mg
jardiance
boehringer ingelheim (nz) limited - empagliflozin 10mg; ; - film coated tablet - 10 mg - active: empagliflozin 10mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).
jardiance
boehringer ingelheim (nz) limited - empagliflozin 25mg; ; - film coated tablet - 25 mg - active: empagliflozin 25mg excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).